Spranger et al reported that the mechanism by which tumor-intrinsic active β-catenin signaling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. This evidence concerns the gene CTLA4 and neoplasm.